Renal Mechanism of Action/Splay vs. TmG
Launched by ASTRAZENECA · Jul 30, 2008
Trial Information
Current as of July 01, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female subjects
- • Age 18 to 65 years
- • BMI 18 to 35 kg/m2
- • Healthy subjects and subjects with type 2 diabetes mellitus on 1 of the following therapies: diet, sulfonylurea, and/or metformin
- • No evidence of impaired renal function
- Exclusion Criteria:
- • Unwilling or unable to use an acceptable method of birth control
- • Subjects with type 1 diabetes mellitus, heart disease, hepatic C or B
- • Exposure to insulin
- • Use of exclusionary concomitant medications
- • Evidence of significant kidney disease or any other significant medical or psychiatric disorder
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials